EGFR and non-small cell lung carcinoma: For instance, EGFR inhibitor gefitinib extended the median progression-free survival by only 5 months compared to conventional chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR mutation (Maemondo et al., 2010).